NASDAQ:PHAT
Phathom Pharmaceuticals, Inc. Stock News
$11.05
+0.550 (+5.24%)
At Close: Mar 27, 2024
Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion
01:19am, Monday, 18'th Mar 2024
The FDA has set a target action date of July 19, 2024, for expanded approval of Voquenza, which would target the larger Non-Erosive GERD patient population. The global market for GERD therapies is exp
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript
02:11pm, Thursday, 07'th Mar 2024
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
08:00am, Wednesday, 31'st Jan 2024
FLORHAM PARK, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharma Is A Buy Before July PDUFA
06:41am, Monday, 01'st Jan 2024
Phathom Pharmaceuticals' stock is down 35% from its August highs and is now trading at $9. The company has two approved indications for its drug vonoprazan and an upcoming PDUFA. Phathom has a cash ba
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
08:01am, Wednesday, 25'th Oct 2023
FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Following Up On Phathom Pharmaceuticals
12:43pm, Thursday, 05'th Oct 2023
Phathom Pharmaceuticals is a small biopharma firm focused on developing treatments for gastrointestinal diseases. The company has recently filed some marketing applications around its primary drug can
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 05'th Sep 2023
FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
02:34pm, Monday, 07'th Aug 2023
One of the safest sectors on the market is biotech. After all, we can't stop people from aging — at least not yet.
Phathom Pharma: Time To Take Profits (Rating Downgrade)
04:12pm, Friday, 14'th Jul 2023
Phathom Pharmaceuticals, Inc. is trading near 52-week highs. Despite its potential, there are reasons, like a competitive market, why we should take profits on Phathom Pharmaceuticals. If it falls bac
3 Top Breakout Stocks Worth a Buy for Attractive Returns
10:08am, Friday, 07'th Jul 2023
Phathom Pharmaceuticals (PHAT), Universal Stainless & Alloy Products (USAP) and Arlo Technologies (ARLO) are the breakout picks for today.
Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?
11:05am, Thursday, 01'st Jun 2023
The mean of analysts' price targets for Phathom Pharmaceuticals, Inc. (PHAT) points to an 81.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong a
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
11:05am, Friday, 26'th May 2023
Phathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong
Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross?
11:01am, Thursday, 25'th May 2023
Phathom Pharmaceuticals, Inc. (PHAT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PHAT's 50-day simple moving average broke out a
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 12'th Apr 2023
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update
09:54am, Wednesday, 05'th Apr 2023
Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection.